Molecular Pathology of Lung Cancer

Collection and Handling of Thoracic Small Biopsy and Cytology Specimens for Ancillary Studies: Guideline From the College of American Pathologists in Collaboration With the American College of Chest Physicians, Association for Molecular Pathology, American Society of Cytopathology, American Thoracic Society, Pulmonary Pathology Society, Papanicolaou Society of Cytopathology, Society of Interventional Radiology, and Society of Thoracic Radiology

(2020) Sinchita Roy-Chowdhuri et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

The rapidly evolving landscape of biomarker testing in non–small cell lung cancer

(2020) Paul A. VanderLaan et al.   CANCER CYTOPATHOLOGY

Current and future trends in non–small cell lung cancer biomarker testing: The American experience

(2020) Paul A. VanderLaan et al.   CANCER CYTOPATHOLOGY

KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors

(2020) David S. Hong et al.   NEW ENGLAND JOURNAL OF MEDICINE

Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung Cancer

(2020) Jürgen Wolf et al.   NEW ENGLAND JOURNAL OF MEDICINE

Invited review—next-generation sequencing: a modern tool in cytopathology

(2019) Sinchita Roy-Chowdhuri et al.   VIRCHOWS ARCHIV

Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer

(2019) Alessandro Leonetti et al.   BRITISH JOURNAL OF CANCER

Systemic Therapy for Locally Advanced and Metastatic Non–Small Cell Lung Cancer

(2019) Kathryn C. Arbour et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee

(2019) Sylvie Lantuejoul et al.   Journal of Thoracic Oncology

Key Issues in Molecular Cytopathology

(2018) Giancarlo Troncone et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology

(2018) Neal I. Lindeman et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update

(2018) Gregory P. Kalemkerian et al.   JOURNAL OF CLINICAL ONCOLOGY

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors

(2018) Neal I. Lindeman et al.   Journal of Thoracic Oncology

Molecular testing of residual cytology samples: Rethink, reclaim, repurpose

(2018) Sinchita Roy-Chowdhuri   CANCER CYTOPATHOLOGY

Targeting MET Exon 14 Skipping Alterations: Has Lung Cancer MET Its Match?

(2017) Timothy A. Yap et al.   Journal of Thoracic Oncology

Targeting MET in Lung Cancer: Will Expectations Finally Be MET?

(2017) Alexander Drilon et al.   Journal of Thoracic Oncology

PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project

(2017) Fred R. Hirsch et al.   Journal of Thoracic Oncology

Precision Diagnosis and Treatment for Advanced Non–Small-Cell Lung Cancer

(2017) Martin Reck et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies

(2017) Emmet J. Jordan et al.   Cancer Discovery

Characteristics of percutaneous core biopsies adequate for next generation genomic sequencing

(2017) Sharjeel H. Sabir et al.   PLoS One

Liquid Biopsy in Lung Cancer: A Perspective From Members of the Pulmonary Pathology Society

(2016) Lynette M. Sholl et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

Cytology Specimens: A Goldmine for Molecular Testing

(2016) Natasha Rekhtman et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

Comprehensive Genomic Profiling Facilitates Implementation of the National Comprehensive Cancer Network Guidelines for Lung Cancer Biomarker Testing and Identifies Patients Who May Benefit From Enrollment in Mechanism-Driven Clinical Trials

(2016) James H. Suh et al.   ONCOLOGIST

Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer

(2015) Anna F. Farago et al.   Journal of Thoracic Oncology

Programmed Death-Ligand 1 Immunohistochemistry in Lung Cancer: In what state is this art?

(2015) Keith M. Kerr et al.   Journal of Thoracic Oncology

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

(2015) Edward B. Garon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

(2015) N. A. Rizvi et al.   SCIENCE

Emerging Science and Therapies in Non-small-Cell Lung Cancer: Targeting the MET Pathway

(2014) Mark G. Kris et al.   Clinical Lung Cancer

Comprehensive molecular profiling of lung adenocarcinoma

(2014) Eric A. Collisson et al.   NATURE

TRKing Down an Old Oncogene in a New Era of Targeted Therapy

(2014) Aria Vaishnavi et al.   Cancer Discovery

Feasibility of Image-Guided Transthoracic Core-Needle Biopsy in the BATTLE Lung Trial

(2013) Alda L. Tam et al.   Journal of Thoracic Oncology

Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer

(2013) Aria Vaishnavi et al.   NATURE MEDICINE